InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.13
(
0.00%
)
Bitcoin
66,349.36
(
-0.43%
)
Post# of 252212
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119847
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 225970

Saturday, 03/14/2020 12:15:12 PM

Saturday, March 14, 2020 12:15:12 PM

Post# of 252212
NBRV—(-43% Friday)—reports $93K Xenleta sales in 4Q19:

https://finance.yahoo.com/news/nabriva-therapeutics-reports-fourth-quarter-200110344.html

The $93K sales figure for 4Q19 not a typo! Cumulative Xenleta sales since the Aug 2019 FDA approval are only $1.5M.

h/t ‘rkrw’ for catching typo in earlier version of this message.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up